ME02486B - Sigma ligandi za primjenu u prevenciji 1/ili lijecenju postoperaтivnog bola - Google Patents
Sigma ligandi za primjenu u prevenciji 1/ili lijecenju postoperaтivnog bolaInfo
- Publication number
- ME02486B ME02486B MEP-2016-112A MEP11216A ME02486B ME 02486 B ME02486 B ME 02486B ME P11216 A MEP11216 A ME P11216A ME 02486 B ME02486 B ME 02486B
- Authority
- ME
- Montenegro
- Prior art keywords
- substituted
- unsubstituted
- sigma ligand
- use according
- aromatic
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims 14
- 230000002265 prevention Effects 0.000 title claims 2
- 208000004550 Postoperative Pain Diseases 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 150000002431 hydrogen Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- 238000011477 surgical intervention Methods 0.000 claims 3
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000001387 Causalgia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 229940122490 Sigma receptor antagonist Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229940125425 inverse agonist Drugs 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000037816 tissue injury Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (10)
1.Sigma ligand za prijmenu u prevenciji i/ili liječenju bola nastalog kao posledica hirurške intervencije, pri čemu sigma ligand ima opštu formulu (I):pri čemuR1 je izabran iz grupe koju čine vodonik, supstituisani ili nesupstituisani alkil, supstituisani ili nesupstituisani cikloalkil, supstituisani ili nesupstituisani alkenil, supstituisani ili nesupstituisani aril, supstituisani ili nesupstituisani arilalkil, supstituisani ili nesupstituisani nearomatični heterociklil, supstituisani ili nesupstituisani aromatični heterociklil, supstituisani ili nesupstituisani heterociklilalkil, -COR8, -C(O)OR8,-C(O)NR8R9, -CH=NR8, -CN, -OR8, -OC(O)R8, -S(O) t-R8, -NR8R9, - NR8C(O)R9, -NO2, -N=CR8R9, i halogen;R2 je izabran iz grupe koju čine vodonik, supstituisani ili nesupstituisani alkil, supstituisani ili nesupstituisani cikloalkil, supstituisani ili nesupstituisani alkenil, supstituisani ili nesupstituisani aril, supstituisani ili nesupstituisani arilalkil, supstituisani ili nesupstituisani, aromatični ili nearomatični heterociklil, supstituisani ili nesupstituisani heterocikilalkil, -COR8, -C(O)OR8, -C(O)NR8R9, -CH=NR8, -CN, -OR8, -OC(O)R8, -S(O)t-R8, -NR8R9, -NR8C(O)R9, -NO2, -N=CR8R9, i halogen;R3 i R4 su nezavisno izabrani iz grupe koju čine vodonik, supstituisani ili nesupstituisani alkil, supstituisani ili nesupstituisani cikloalkil, supstituisani ili nesupstituisani alkenil, supstituisani ili nesupstituisani aril, supstituisani ili nesupstituisani arilalkil, supstituisani ili nesupstituisani, aromatični ili nearomatični heterociklil, supstituisani ili nesupstituisani heterociklilalkil, -COR8, -C(O)OR8, -C(O)NR8R9, -CH=NR8, -CN, -OR8,-OC(O)R8, -S(O)t-R8, -NR8R9, -NR8C(O)R9, -NO2, -N=CR8R9, i halogen, ili oni zajedno obrazuju opciono supstituisani kondenzovani prstenasti sistem;R5 i R6 su nezavisno izabrani iz grupe koju čine vodonik, supstituisani ili nesupstituisani alkil, substituted ili nesupstituisani cikloalkil, supstituisani ili nesupstituisani alkenil, supstituisani ili nesupstituisani aril, supstituisani ili nesupstituisani arilalkil, supstituisani ili nesupstituisani, aromatični ili nearomatični heterociklil, supstituisani ili nesupstituisani heterociklil alkil, -COR8, -C(O)OR8, -C(O)NR8R9, -CH=NR8, -CN, -OR8,-OC(O)R8, -S(O)t-R8, -NR8R9, -NR8C(O)R9, -NO2, -N=CR8R9, i halogen, ili zajedno obrazuju, sa atomom azota za koji su vezani, supstituisanu ili nesupstituisanu, aromatičnu ili nearomatičnu heterocikličnu grupu;n je izabran između 1, 2, 3, 4, 5, 6, 7 i 8;t je 1,2 ili 3;svaki R8 i R9 je nezavisno izabran između sledećeg: vodonik, supstituisani ili nesupstituisani alkil, supstituisani ili nesupstituisani cikloalkil, supstituisani ili nesupstituisani alkenil, supstituisani ili nesupstituisani aril, supstituisani ili nesupstituisani, aromatični ili nearomatični heterociklil, supstituisani ili nesupstituisani alkoksi, supstituisani ili nesupstituisani ariloksi, i halogen;ili njegove farmaceutski prihvatljive soli, stereoizomeri ili solvati.
2.Sigma ligand za primjenu prema zahtjevu 1, pri čemu je bol izabran između akutnog i/ili hroničnog bola nastalog kao posledica hirurške intervencije.
3.Sigma ligand za primjenu prema zahtjevu 2, pri čemu je bol izabran između površinskog i/ili dubokog bola zbog sekundarne povrede tkiva prilikom hirurške intervencije, i/ili neuropatskog bola, neuralgije, alodinije, kauzalgije, hiperalgezije, hiperestezije, hiperpatije, neuritisa i neuropatije nastalih posle hirurške procedure.
4.Sigma ligand za primjenu prema prema bilo kom od prethodnih zahtjeva, koji je izabran između antagonista sigma receptora, a prvenstveno je izabran između neutralnog antagonista, inverznog agonista ili delimičnog antagonista.
5.Sigma ligand za primjenu prema prema bilo kom od prethodnih zahtjeva, pri čemu je R1 izabran između H, -COR8 i supstituisanog ili nesupstituisanog alkila.
6.Sigma ligand za primjenu prema prema bilo kom od prethodnih zahtjeva, pri čemu R2 je H ili alkil.
7.Sigma ligand za primjenu prema prema bilo kom od prethodnih zahtjeva, pri čemu R3 i R4 zajedno obrazuju kondenzovani naftil prstenasti sistem.
8.Sigma ligand za primjenu prema prema bilo kom od prethodnih zahtjeva, pri čemu R5 i R6 zajedno obrazuju morfolin-4-il grupu.
9.Sigma ligand za primjenu prema prema bilo kom od prethodnih zahtjeva, pri čemu je sigma ligand 4-{2-[5-metil-1-(naftalenlen-2-il)-1H-pirazol-3-iloksi]etil} morfolin, ili njegova farmaceutski prihvatljiva so, stereoizomer ili solvat.
10.Sigma ligand za primjenu prema prema bilo kom od prethodnih zahtjeva, pri čemu je sigma ligand 4-{2-[5-metil-1-(naftalenlen-2-il)-1H-pirazol-3-iloksi]etil} morfolin hidrohlorid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382024A EP2353598A1 (en) | 2010-02-04 | 2010-02-04 | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP11702057.8A EP2531191B1 (en) | 2010-02-04 | 2011-02-04 | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| PCT/EP2011/051643 WO2011095584A1 (en) | 2010-02-04 | 2011-02-04 | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02486B true ME02486B (me) | 2017-02-20 |
Family
ID=42091519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-112A ME02486B (me) | 2010-02-04 | 2011-02-04 | Sigma ligandi za primjenu u prevenciji 1/ili lijecenju postoperaтivnog bola |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9844516B2 (me) |
| EP (2) | EP2353598A1 (me) |
| JP (1) | JP5926691B2 (me) |
| KR (1) | KR101708447B1 (me) |
| CN (2) | CN106924264A (me) |
| AR (1) | AR080134A1 (me) |
| AU (1) | AU2011212389B2 (me) |
| BR (1) | BR112012018960A2 (me) |
| CA (1) | CA2788029C (me) |
| CO (1) | CO6602137A2 (me) |
| CY (1) | CY1117651T1 (me) |
| DK (1) | DK2531191T3 (me) |
| EC (1) | ECSP12012038A (me) |
| ES (1) | ES2576844T3 (me) |
| HR (1) | HRP20160695T1 (me) |
| HU (1) | HUE027562T2 (me) |
| IL (1) | IL221275A (me) |
| MA (1) | MA34045B1 (me) |
| ME (1) | ME02486B (me) |
| MX (1) | MX2012008193A (me) |
| MY (1) | MY162905A (me) |
| NZ (1) | NZ601131A (me) |
| PH (1) | PH12012501508A1 (me) |
| PL (1) | PL2531191T3 (me) |
| PT (1) | PT2531191E (me) |
| RS (1) | RS55036B1 (me) |
| RU (1) | RU2569055C2 (me) |
| SG (2) | SG10201500868WA (me) |
| SI (1) | SI2531191T1 (me) |
| SM (1) | SMT201600182B (me) |
| TN (1) | TN2012000349A1 (me) |
| TW (1) | TWI585083B (me) |
| UA (1) | UA111148C2 (me) |
| WO (1) | WO2011095584A1 (me) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2426111A1 (en) * | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| RU2469712C2 (ru) * | 2010-12-16 | 2012-12-20 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО "МОНИКИ им. М.Ф. Владимирского") | Способ профилактики и лечения послеоперационного болевого синдрома при торакоскопических операциях |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2818166A1 (en) * | 2013-06-26 | 2014-12-31 | Laboratorios del Dr. Esteve S.A. | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) |
| AU2014320399A1 (en) * | 2013-09-12 | 2016-03-10 | Laboratorios Del Dr. Esteve, S.A. | NSAID and Sigma receptor ligand combinations |
| TW201607538A (zh) | 2013-12-17 | 2016-03-01 | 以斯提夫博士實驗室股份有限公司 | 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物 |
| CN106456578B (zh) | 2014-02-07 | 2020-02-18 | 匈牙利科学院大学及其他机构附属研究所 | Sigma-1受体激动剂化合物的用途 |
| MA41177A (fr) * | 2014-12-15 | 2017-10-24 | Esteve Labor Dr | Utilisation de ligands des récepteurs sigma dans l'arthrose |
| EP3233830A1 (en) * | 2014-12-15 | 2017-10-25 | Laboratorios Del. Dr. Esteve, S.A. | 1-methylpyrazole-piperazine compounds having multimodal activity against pain |
| CN107868033B (zh) * | 2016-09-27 | 2021-05-18 | 深圳微芯生物科技股份有限公司 | 一种苯丙氨酸类化合物的制备方法 |
| US10195192B2 (en) * | 2016-11-01 | 2019-02-05 | Anavex Life Sciences Corp. | Analgesic therapeutic and method, 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof |
| WO2018096376A1 (en) | 2016-11-24 | 2018-05-31 | Mta Támogatott Kutatócsoportok Irodája | Compositions for organ preservation |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU11248A1 (ru) | 1927-03-29 | 1929-09-30 | В.С. Григорьев | Способ очистки антрацена |
| US3428634A (en) | 1965-03-13 | 1969-02-18 | Acraf | 3-tertiary amino alkoxy-1-hydrocarbon indazoles |
| IT1005472B (it) | 1974-02-15 | 1976-08-20 | Montedison Spa | Procedimento per la preparazione del 2,5, dimetil 3,2h, furanone |
| FR2301250A1 (fr) | 1975-02-21 | 1976-09-17 | Bellon Labor Sa Roger | Nouveaux diaryl-1, 4o-aminoalcoxy-3 pyrazoles et leurs sels |
| CA1121651A (en) | 1978-07-27 | 1982-04-13 | Chi-Kuen Shu | 2,5-dialkyl dihydrofuranones and 2,4,5-trialkyl dihydrofuranones, mixtures of same and organoleptic uses thereof |
| FR2472564A1 (fr) | 1979-12-31 | 1981-07-03 | Bellon Labor Sa Roger | Nouveaux aryl-1 arylsulfonyl-4 1h-pyrazolols-3, et procede pour les preparer |
| US4826868A (en) | 1986-05-29 | 1989-05-02 | Ortho Pharmaceutical Corporation | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
| GB8917069D0 (en) | 1989-07-26 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| JPH03232817A (ja) | 1990-02-07 | 1991-10-16 | Showa Yakuhin Kako Kk | 貼付剤 |
| EP0445974A3 (en) | 1990-03-05 | 1992-04-29 | Merck Sharp & Dohme Ltd. | Spirocyclic antipsychotic agents |
| JPH04364129A (ja) | 1990-10-26 | 1992-12-16 | Asahi Chem Ind Co Ltd | ６−置換アルコキシキノキサリン誘導体含有医薬組成物およびその製造法 |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| US5240925A (en) | 1991-08-26 | 1993-08-31 | Rohm And Haas Company | Fungicidal 2-aryl-2-cyano-2-(heterocyclylalkyl)ethyl-1,2,4-triazoles |
| JP3856816B2 (ja) | 1992-05-20 | 2006-12-13 | ノースウェスターン ユニヴァーシティ | 抗発作治療用のｇａｂａ及びｌ−グルタミン酸類縁体 |
| GB9423542D0 (en) | 1994-11-22 | 1995-01-11 | Marples Brian A | Pharmaceutical compounds |
| JPH1036259A (ja) | 1996-04-11 | 1998-02-10 | Kikkoman Corp | 白内障の予防または治療薬剤 |
| JPH1055048A (ja) | 1996-08-08 | 1998-02-24 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| DK0975648T3 (da) | 1997-04-14 | 2003-09-29 | Ufc Ltd | Morfinderivater |
| CN1106390C (zh) | 1997-07-02 | 2003-04-23 | 麦克公司 | 速激肽受体拮抗剂2－(r)－(1－(r)－(3,5－二(三氟甲基)苯基)乙氧基)－3－(s)－(4－氟)苯基－4－(3－(5－氧代－1h,4h－1,2,4－三唑)甲基码啉的晶型 |
| BR9813284B1 (pt) | 1997-10-27 | 2012-08-21 | aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos e composição farmacêutica. | |
| DE69826151T2 (de) | 1997-12-16 | 2005-01-27 | Warner-Lambert Co. Llc | 1-substituierte-1-aminomethyl-cycloalkan derivate (= gabapentin analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen |
| IL135314A0 (en) | 1997-12-16 | 2001-05-20 | Warner Lambert Co | Novel amines as pharmaceutical agents |
| IL135315A0 (en) | 1997-12-16 | 2001-05-20 | Warner Lambert Co | 4(3)-substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| WO1999059409A1 (en) | 1998-05-21 | 1999-11-25 | Matsumoto Rae R | Compounds and uses thereof |
| JP2002516312A (ja) | 1998-05-26 | 2002-06-04 | ワーナー−ランバート・カンパニー | カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物 |
| WO2000020005A1 (en) | 1998-10-01 | 2000-04-13 | EGIS Gyógyszergyár Rt. | Pharmaceutical compositions containing an opiate analgesic and a synergizing substance |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| EP1130018B1 (en) | 1998-11-09 | 2007-01-17 | Santen Pharmaceutical Co., Ltd. | Drug dependence remedy |
| US6627771B1 (en) | 1998-11-25 | 2003-09-30 | Pfizer Inc | Gamma amino butyric and acid analogs |
| NO310544B1 (no) | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
| BR0010961A (pt) | 1999-05-26 | 2002-03-26 | Warner Lambert Co | Composto, composição farmacêutica, e, métodos para tratar epilepsia, ataques de tontura, hipocinésia, e distúrbios cranianos, distúrbios neurodegenerativos, depressão, ansiedade, pânico, dor, distúrbios neuropatológicos e distúrbios do sono |
| ES2185591T3 (es) | 1999-06-02 | 2003-05-01 | Warner Lambert Co | Amino hererociclos utiles como agentes farmaceuticos. |
| IL157932A0 (en) | 2001-04-19 | 2004-03-28 | Warner Lambert Co | Fused bicyclic or tricyclic amino acids |
| CA2446864C (en) | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
| WO2002102387A1 (en) | 2001-06-18 | 2002-12-27 | H. Lundbeck A/S | Treatment of neuropathic pain |
| RU2218187C2 (ru) | 2002-02-11 | 2003-12-10 | Ростовский научно-исследовательский онкологический институт | Способ лечения болевого синдрома у онкологических больных |
| GB0206505D0 (en) | 2002-03-19 | 2002-05-01 | Euro Celtique Sa | Pharmaceutical combination |
| WO2004016592A1 (en) | 2002-08-14 | 2004-02-26 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| TW200413351A (en) | 2002-08-21 | 2004-08-01 | Astrazeneca Ab | Chemical compounds |
| EP1560820B1 (en) | 2002-11-15 | 2010-05-26 | E.I. Du Pont De Nemours And Company | Novel anthranilamide insecticides |
| JP2004196678A (ja) | 2002-12-17 | 2004-07-15 | Dainippon Pharmaceut Co Ltd | ピラゾール系誘導体 |
| WO2005061462A2 (en) | 2003-12-19 | 2005-07-07 | Neurogen Corporation | Diaryl pyrazole derivatives and their use as neurokinin-3 receptor modulators |
| MX2007000793A (es) | 2004-07-24 | 2007-03-21 | Esteve Labor Dr | Uso de compuestos activos sobre el receptor sigma para el tratamiento de alodinia mecanica. |
| BRPI0514736A (pt) | 2004-08-27 | 2008-06-24 | Esteve Labor Dr | inibidores do receptor sigma |
| ES2251317B1 (es) * | 2004-10-14 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Inhibidores del receptor sigma. |
| EP1634873A1 (en) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| ES2251316B1 (es) | 2004-10-14 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Inhibidores del receptor sigma. |
| WO2006021462A1 (en) | 2004-08-27 | 2006-03-02 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| EP1634872A1 (en) * | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
| EP1632227A1 (en) | 2004-09-07 | 2006-03-08 | Laboratorios del Dr. Esteve S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction |
| JP2008179541A (ja) * | 2005-05-02 | 2008-08-07 | Mochida Pharmaceut Co Ltd | 神経因性疼痛治療薬 |
| NZ564916A (en) | 2005-06-27 | 2011-03-31 | Exelixis Inc | Imidazole based LXR modulators |
| WO2007025613A2 (en) | 2005-07-15 | 2007-03-08 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| EP1787679A1 (en) * | 2005-07-29 | 2007-05-23 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain |
| US7872006B2 (en) | 2005-10-21 | 2011-01-18 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity |
| WO2007079086A1 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Pyrazoloalkyl substituted imidazo ring compounds and methods |
| EP1820502A1 (en) | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
| EP1991211A1 (en) | 2006-02-28 | 2008-11-19 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome |
| EP1829875A1 (en) | 2006-03-01 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
| EP1829873A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Pyrrazole derivatives as sigma receptors antagonists |
| EP1829866A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| CN101404933B (zh) | 2006-03-22 | 2010-12-15 | 松下电器产业株式会社 | 血液检查装置 |
| EP2012774A1 (en) | 2006-03-27 | 2009-01-14 | Wex Pharmaceuticals, Inc | Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| EP1847542A1 (en) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor |
| AU2007256352A1 (en) | 2006-06-08 | 2007-12-13 | Ucb Pharma Gmbh | Therapeutic combination for painful medical conditions |
| RU2322977C1 (ru) | 2006-08-01 | 2008-04-27 | Закрытое акционерное общество "Физиофарм" | Синтетическое анальгетическое средство и способ лечения на основе этого средства |
| WO2008015266A1 (en) * | 2006-08-04 | 2008-02-07 | Laboratorios Del Dr. Esteve, S.A. | Substituted dimethylcyclobutyl compounds, their preparation and use in medicaments |
| EP1921073A1 (en) | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazole derivatives as sigma receptor inhibitors |
| KR100868353B1 (ko) | 2007-03-08 | 2008-11-12 | 한국화학연구원 | 도파민 ｄ4 수용체 길항제인 신규 피페라지닐프로필피라졸유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
| GB0710981D0 (en) | 2007-06-07 | 2007-07-18 | Acacia Pharma Ltd | New Therapeutic use |
| JPWO2009038112A1 (ja) | 2007-09-21 | 2011-01-06 | 塩野義製薬株式会社 | Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤 |
| EP2070933A1 (en) | 2007-12-07 | 2009-06-17 | Laboratorios del Dr. Esteve S.A. | Tricyclic triazolic compounds |
| EP2090311A1 (en) | 2008-02-18 | 2009-08-19 | Laboratorios Del. Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| BRPI0908217A2 (pt) | 2008-02-18 | 2015-08-25 | Esteve Labor Dr | Uso de compostos de ligação aos ligantes do receptor sigma para o tratamento de dor neuropática desenvolvida como uma consequência de quimioterapia |
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2113501A1 (en) | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors |
| EP2112139A1 (en) | 2008-04-25 | 2009-10-28 | Laboratorios Del. Dr. Esteve, S.A. | Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors |
| RU2382646C1 (ru) | 2008-11-20 | 2010-02-27 | Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального агентства по высокотехнологичной медицинской помощи" | Способ профилактики и лечения послеоперационного болевого синдрома при обширных торакоабдоминальных операциях |
| EP2292236A1 (en) | 2009-08-14 | 2011-03-09 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| WO2011064315A1 (en) | 2009-11-25 | 2011-06-03 | Laboratorios Del Dr. Esteve, S.A. | 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts |
| EP2335688A1 (en) | 2009-11-25 | 2011-06-22 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compositions comprising sigma receptor ligands |
| EP2361904A1 (en) | 2010-02-04 | 2011-08-31 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| SI2531177T1 (sl) | 2010-02-04 | 2016-10-28 | Laboratorios Del Dr. Esteve, S.A. | 4-(2-((5-metil-1(2-naftalenil)-1h-pirazol-3-il)oksi)etil)morpholin hidroklorid polimorfi in solvati |
| EP2426112A1 (en) | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2395003A1 (en) | 2010-05-27 | 2011-12-14 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2426111A1 (en) | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| EP2460519A1 (en) | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
| EP2460804A1 (en) | 2010-12-03 | 2012-06-06 | Laboratorios Del Dr. Esteve, S.A. | 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics |
| SG10201913053QA (en) | 2011-05-13 | 2020-03-30 | Array Biopharma Inc | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2792352A1 (en) | 2013-04-16 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Alpha-2 adrenoreceptor and sigma receptor ligand combinations |
| FR3005127B1 (fr) | 2013-04-29 | 2015-04-17 | Chassis Brakes Int Bv | "frein a disque a patin de freins stabilises, et procedes associes d'assemblage et de remplacement d'un patin" |
| EP2818166A1 (en) | 2013-06-26 | 2014-12-31 | Laboratorios del Dr. Esteve S.A. | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS) |
| AU2014320399A1 (en) | 2013-09-12 | 2016-03-10 | Laboratorios Del Dr. Esteve, S.A. | NSAID and Sigma receptor ligand combinations |
| AU2014364644A1 (en) | 2013-12-17 | 2016-06-23 | Laboratorios Del Dr. Esteve, S.A. | Gabapentinoids and Sigma receptor ligands combinations |
| TW201607538A (zh) | 2013-12-17 | 2016-03-01 | 以斯提夫博士實驗室股份有限公司 | 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物 |
-
2010
- 2010-02-04 EP EP10382024A patent/EP2353598A1/en not_active Withdrawn
-
2011
- 2011-02-04 MA MA35181A patent/MA34045B1/fr unknown
- 2011-02-04 CA CA2788029A patent/CA2788029C/en not_active Expired - Fee Related
- 2011-02-04 MX MX2012008193A patent/MX2012008193A/es active IP Right Grant
- 2011-02-04 SI SI201130843A patent/SI2531191T1/sl unknown
- 2011-02-04 WO PCT/EP2011/051643 patent/WO2011095584A1/en not_active Ceased
- 2011-02-04 BR BR112012018960A patent/BR112012018960A2/pt not_active Application Discontinuation
- 2011-02-04 NZ NZ601131A patent/NZ601131A/en not_active IP Right Cessation
- 2011-02-04 EP EP11702057.8A patent/EP2531191B1/en active Active
- 2011-02-04 DK DK11702057.8T patent/DK2531191T3/en active
- 2011-02-04 HU HUE11702057A patent/HUE027562T2/en unknown
- 2011-02-04 SG SG10201500868WA patent/SG10201500868WA/en unknown
- 2011-02-04 AU AU2011212389A patent/AU2011212389B2/en not_active Ceased
- 2011-02-04 PL PL11702057T patent/PL2531191T3/pl unknown
- 2011-02-04 ME MEP-2016-112A patent/ME02486B/me unknown
- 2011-02-04 AR ARP110100381A patent/AR080134A1/es unknown
- 2011-02-04 ES ES11702057.8T patent/ES2576844T3/es active Active
- 2011-02-04 HR HRP20160695TT patent/HRP20160695T1/hr unknown
- 2011-02-04 JP JP2012551632A patent/JP5926691B2/ja not_active Expired - Fee Related
- 2011-02-04 US US13/574,940 patent/US9844516B2/en not_active Expired - Fee Related
- 2011-02-04 PT PT117020578T patent/PT2531191E/pt unknown
- 2011-02-04 CN CN201710099661.8A patent/CN106924264A/zh active Pending
- 2011-02-04 KR KR1020127023171A patent/KR101708447B1/ko not_active Expired - Fee Related
- 2011-02-04 RU RU2012137501/15A patent/RU2569055C2/ru not_active IP Right Cessation
- 2011-02-04 CN CN2011800083102A patent/CN102781445A/zh active Pending
- 2011-02-04 RS RS20160430A patent/RS55036B1/sr unknown
- 2011-02-04 MY MYPI2012003370A patent/MY162905A/en unknown
- 2011-02-04 SG SG2012053716A patent/SG182627A1/en unknown
- 2011-02-04 PH PH1/2012/501508A patent/PH12012501508A1/en unknown
- 2011-02-08 TW TW100104114A patent/TWI585083B/zh not_active IP Right Cessation
- 2011-04-02 UA UAA201210430A patent/UA111148C2/uk unknown
-
2012
- 2012-07-04 TN TNP2012000349A patent/TN2012000349A1/en unknown
- 2012-07-13 EC ECSP12012038 patent/ECSP12012038A/es unknown
- 2012-08-02 IL IL221275A patent/IL221275A/en not_active IP Right Cessation
- 2012-09-04 CO CO12151307A patent/CO6602137A2/es not_active Application Discontinuation
-
2016
- 2016-06-16 SM SM201600182T patent/SMT201600182B/it unknown
- 2016-06-17 CY CY20161100541T patent/CY1117651T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02486B (me) | Sigma ligandi za primjenu u prevenciji 1/ili lijecenju postoperaтivnog bola | |
| AR081623A1 (es) | Ligandos sigma para la potenciacion del efecto analgesico de opioides y opiatos en el dolor posoperatorio y la atenuacion de la dependencia a los mismos | |
| AR084730A1 (es) | Ligandos heterociclicos nitrogenados de receptores sigma utiles para el tratamiento de dolor por cancer de huesos | |
| AR082441A1 (es) | Uso de ligandos sigma en la hiperalgesia inducida por opioides | |
| HRP20171453T1 (hr) | Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita | |
| MX2018002399A (es) | Compuestos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos. | |
| JP2015531773A5 (me) | ||
| HRP20200586T1 (hr) | Karbamoiloksimetil triazol cikloheksilne kiseline kao antagonisti lpa | |
| MX2014012454A (es) | Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria. | |
| RU2018121145A (ru) | Лекарственный препарат для лечения гриппа, характеризующийся тем, что в нем объединены ингибитор кэп-зависимой эндонуклеазы и лекарственное средство против гриппа | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| PE20131143A1 (es) | Nuevas aminopirazoloquinazolinas | |
| IL298983A (en) | Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors | |
| MY187617A (en) | Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| JP2016534134A5 (me) | ||
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| PE20212253A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
| AR079199A1 (es) | Composiciones farmaceuticas que comprenden ligandos de receptores sigma | |
| JP2016518434A5 (me) | ||
| ME02583B (me) | Jedinjenja pirolidinil uree, pirolidinil tiouree i pirolidinil guanidina kao inhibitori trka kinaze | |
| CO6410301A2 (es) | 1 aril -3- aminoalcoxi-pirazoles como ligandos sigma para potenciar ell efecto analgesico de los opioides y atenuar la dependencia de ellos | |
| AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
| MX2014012741A (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activado de proteasa (par4) para tratamiento de agregacion plaquetaria. | |
| JP2015535839A5 (me) |